Evaluation of humoral and cellular immune response of BALB/c mice immunized with a recombinant fragment of MSP1a from Anaplasma marginale using carbon nanotubes as a carrier molecule

Vaccine. 2014 Apr 17;32(19):2160-6. doi: 10.1016/j.vaccine.2014.02.062. Epub 2014 Mar 4.

Abstract

Bovine anaplasmosis is a disease caused by the intraerythrocytic rickettsia Anaplasma marginale. Surface proteins (MSPs) of A. marginale are important in the interaction of the pathogen with the host and constitute potential vaccine targets against this pathogen. Currently, there is no commercial inactivated vaccine against bovine anaplasmosis that can generate a protective immune response that effectively prevents the development of clinical disease. The objective of this study was to evaluate the humoral and cellular immune responses of BALB/c mice immunized with the recombinant fragment of rMSP1a from A. marginale using carbon nanotubes as a carrier molecule. The fragment of rMSP1a comprising the N-terminal region of the protein was expressed in Escherichia coli BL21, purified by nickel affinity chromatography and covalently linked to multiwalled carbon nanotubes (MWNTs). After this functionalization, thirty BALB/c mice were divided into five groups, G1 (rMSP1a), G2 (MWNT+rMSP1a), G3 (MWNT), G4 (adjuvant) and G5 (unimmunized). The mice were immunized subcutaneously at days 0, 21 and 42. Blood samples were collected on day 11 after immunization. The spleens were collected, and the splenocytes were cultured for cell proliferation assays and cell immunophenotyping. Mice immunized with rMSP1a (G1 and G2) produced high levels of anti-rMSP1a IgG, demonstrating that the functionalization to carbon nanotubes did not interfere with protein immunogenicity. Immunization with MWNT+rMSP1a significantly induced higher percentages of CD4(+)CD44(+) and CD4(+)CD62L(+) lymphocytes, high levels of TNF-α, and a higher proliferative rate of splenocytes compared to mice immunized with rMSP1a alone (G1 group). Therefore, additional experiments using cattle should be performed to determine the efficacy, safety, immunogenicity and protection induced by rMSP1a associated with MWNT.

Keywords: Anaplasma marginale; Carbon nanotubes; Vaccine; rMSP1a.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaplasma marginale
  • Anaplasmosis / prevention & control*
  • Animals
  • Antibodies, Bacterial / blood
  • Bacterial Outer Membrane Proteins / immunology*
  • Bacterial Vaccines / chemistry
  • Bacterial Vaccines / immunology*
  • Cells, Cultured
  • Cytokines / immunology
  • Drug Carriers / chemistry
  • Epitopes / immunology
  • Female
  • Immunity, Cellular
  • Immunity, Humoral
  • Mice, Inbred BALB C
  • Nanotubes, Carbon / chemistry*
  • Recombinant Proteins / immunology
  • Spleen / cytology
  • Spleen / immunology
  • T-Lymphocytes / immunology

Substances

  • Antibodies, Bacterial
  • Bacterial Outer Membrane Proteins
  • Bacterial Vaccines
  • Cytokines
  • Drug Carriers
  • Epitopes
  • Nanotubes, Carbon
  • Recombinant Proteins
  • major surface protein 1a, Anaplasma